European Commission Grants Conditional Marketing Authorization To Pfizer’s Sutent®
Monday, 07 August 2006
BERKELEY, CA (UroToday.com) - Pfizer Inc said today that Sutent® (sunitinib malate) has received European conditional marketing authorization for advanced and/or metastatic renal cell carcinoma (mRCC), a type of advanced kidney cancer, after failure of interferon alfa and interleukin-2 therapies.
read more
|
Relationship Between Patient Age and the Clinical Characteristics of Renal Cell Carcinoma
Friday, 04 August 2006
BERKELEY, CA (UroToday.com) - Recent studies have suggested a relationship between age and the clinical characteristics of renal cell carcinoma (RCC), where the biology of tumors in younger patients may be quite different from that found in older patients.
read more
|
B7-H1 Tumor Expression is a Marker of Prognosis in Renal Cell Carcinoma
Wednesday, 02 August 2006
BERKELEY, CA (UroToday.com) - UroToday.com - B7-H1 is a tumor associated antigen that participates in T-cell costimulation as a negative regulator of immunity. Tumor expression of this antigen has been shown to be associated with a worse prognosis in renal cell carcinoma (RCC).
read more
|
Is Renal Capsular Invasion, without Perinephric Fat Invasion, a Marker of Aggressive Biology in Renal Cell Carcinoma?
Tuesday, 01 August 2006
BERKELEY, CA (UroToday.com) - Perinephric fat invasion is an accepted pathologic marker of aggressive biology in renal cell carcinoma (RCC). Renal capsule invasion, without perinephric fat invasion, is often reported in pathology reports but is not accounted for in current TNM staging as a distinct classification that differentiates outcome.
read more
|
BJUI Mini Reviews - Minimally Invasive Nephron-Sparing Surgery for Renal Cell Cancer
Tuesday, 01 August 2006
In this review, we examine the principles of MINSS, the salient technical aspects of the procedures, the current results to date, and future concepts.
Login to read more...
|
Defining the Molecular Correlates for the Presence of “Symptomatic” Primary Tumors in Renal Cell Carcinoma
Friday, 28 July 2006
BERKELEY, CA (UroToday.com) - The presence of symptoms (pain, hematuria, systemic malaise, fever, weight loss, etc.) associated with a primary renal cell carcinoma (RCC) tumor has been shown to be a poor prognostic feature in patients with localized disease.
read more
|
Treatment Of Locally Recurrent Renal Cell Carcinoma
Thursday, 27 July 2006
BERKELEY, CA (UroToday.com) - Local recurrence of renal cell carcinoma (RCC) is extremely rare, occurring in less than 2% of patients, with distant metastatic progression far more common.
read more
|
Nexavar® Approved by European Commission for the Treatment of Advanced Kidney Cancer
Wednesday, 26 July 2006
West Haven, CT and Emeryville, CA – Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the European Commission has granted marketing authorization to Nexavar® (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Bayer will commercialize Nexavar in Europe.
read more
|
√ Sunitinib in Patients with Metastatic Renal Cell Carcinoma
Monday, 24 July 2006
√ Editor's Pick: BERKELEY, CA (UroToday.com) - The treatment of advanced renal cell carcinoma [RCC] is undergoing a paradigm shift with the recent introduction of anti-angiogenic therapy that either directly inhibits vascular endothelial growth factor or disrupts signal transduction favorable to vascular development through multi-kinase inhibitors.
read more
|
Overtreatment of Localized Renal Cell Carcinoma: Are We Over Utilizing Developing Technologies Rather Than Letting Disease Biology Dictate Appropriate Treatment?
Friday, 21 July 2006
BERKELEY, CA (UroToday.com) - Recently published studies based on SEER database analyses have suggested that nephron sparing approaches are being vastly underutilized in the surgical treatment of small renal masses.
read more
|
√ Sorafenib In Renal Cell Carcinoma: Results Of the Phase II Placebo-Controlled Randomized Discontinuation Trial
Wednesday, 19 July 2006
√ Editor's Pick: BERKELEY, CA (UroToday.com) - Sorafenib was recently approved by the FDA as a systemic therapy option for metastatic renal cell carcinoma (RCC) in part due to the data from this phase II placebo-controlled randomized discontinuation trial.
read more
|
Differentiating Chromophobe Renal Cell Carcinoma From Oncocytoma Remains A Diagnostic Dilemma That Hampers The Utility Of Renal Mass Biopsy: Contribution Of Caveolin-1 Immunohistochemistry
Thursday, 13 July 2006
BERKELEY, CA (UroToday.com) - The Achille's heel that continues to plague the utility of renal biopsy in the evaluation of renal masses is the reliable differentiation of chromophobe renal cell carcinoma (malignant) from oncocytoma (benign).
read more
|
Urologic Professionals to Learn Latest Practice Advances at Society of Urologic Nurses and Associates Annual Conference
Monday, 10 July 2006
Pitman, NJ - The Society of Urologic Nurses and Associates' (SUNA) will hold its 2006 Annual Conference in Kansas City, MO, October 27-30, 2006, at the Hyatt Regency Crown Center.
read more
|
Phase I Trial Of Carbonic Anhydrase IX (CA9) Peptide Vaccine In Cytokine Refractory Metastatic Renal Cell Carcinoma
Friday, 30 June 2006
BERKELEY, CA (UroToday.com) - CA9 is a tumor associated antigen that is expressed on the majority of renal cell carcinomas (RCC's) as well as other tumors. As a consequence of this finding, several therapeutic strategies have been developed that target CA9, including monoclonal antibody therapy, genetically engineered autologous T cells, and others. Here, Uemura and colleagues report on a vaccine strategy targeting CA9 through the use of CA9 peptides in combination with Freund's adjuvant in cytokine refractory RCC out of Japan.
read more
|
Intermediate Results Of Laparoscopic Cryoablation In 59 Patients At The Medical College Of Wisconsin
Wednesday, 21 June 2006
BERKELEY, CA (UroToday.com) - Among 81 renal tumors in 59 patients, laparoscopic cryoablation was successful in 97.5% at 2.3 years follow-up. The authors did the procedure under control with a laparoscopic ultrasound probe using 5 mm cryoprobes; average lesion size was 2.5 cm. If one limits results to only patients with proven renal cancer, then the success rate would be 94% among 34 patients.
read more
|
Renal Cell Carcinoma In The Pediatric Population
Friday, 16 June 2006
BERKELEY, CA (UroToday.com) - While the incidence of renal cell carcinoma (RCC) is rising, it remains a relatively uncommon malignancy in the pediatric population, where it represents only 2-6% of solid renal malignancies. In this report, Cook and colleagues describe their experience with the management of RCC in childhood, specifically examining the role of partial nephrectomy as a reasonable surgical approach in patients with anatomically amenable tumors.
read more
|
Validation Of The Mayo SSIGN Score As A Prognostic Nomogram In Conventional (Clear Cell) Renal Cell Carcinoma
Thursday, 15 June 2006
BERKELEY, CA (UroToday.com) - Several prognostic nomograms exist to assess the outcome of patients with renal cell carcinoma (RCC). These include the UISS out of UCLA, the Kattan nomogram out of Memorial Sloan-Kettering, and the SSIGN score out of Mayo. A criticism of these and other nomograms is that they are modeled and validated on a single population of patients and may lack the versatility to be extrapolated to other patient samples. Recently, the UISS was externally validated in a multi-institutional dataset that proved its value as a prognostic aid in patients with RCC. Here Ficarra and colleagues, out of the University of Verona in Italy, externally validate the Mayo SSIGN score system.
read more
|
Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
Tuesday, 13 June 2006
Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Nexavar® (sorafenib) tablets has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic hepatocellular carcinoma (HCC), or liver cancer. Nexavar was approved by the FDA in December 2005 for the treatment of patients with advanced renal cell carcinoma (RCC).
read more
|
Is There An Increased Risk Of Other Malignancies In Patients With Renal Cell Carcinoma?
Monday, 12 June 2006
BERKELEY, CA (UroToday.com) - There have been conflicting reports in the literature regarding the association of other malignancies with renal cell carcinoma (RCC). In this study by Beisland and colleagues, out of Norway, the association of RCC with other malignancies is again examined.
read more
|
ASCO 2006 - GU Oral Presentation Renal Cancer
Friday, 09 June 2006
Sunitinib and sorafenib, oral multi-targeted tyrosine kinase inhibitors of the VEGF receptor and PDGF receptor, are approved by the US FDA for the treatment of metastatic RCC. In the ASCO plenary session, Motzer et al. presented a phase III randomized trial comparing sunitinib with interferon-alfa as first line therapy for patients with metastatic Renal cell cancer. This trial demonstrated a significant improvement in progression-free survival in the sunitinib arm. At the oral GU session, two abstracts further our understanding of the role of the oral multi-targeted tyrosine kinase inhibitors of the VEGF receptor and PDGF receptor in the management of metastatic RCC.
read more
|
ASCO 2006 - Plenary Session: Renal Cell Cancer
Tuesday, 06 June 2006
The treatment of patients with metastatic renal cell carcinoma has relied upon the use of cytokine therapy such as interferon-alfa or interleukin-2. These treatments resulted in a minority of patients benefiting. While a small proportion of highly selected patients have derived long-term benefit from cytokine therapy, most do not. The median survival of patients with metastatic renal cell cancer treated with IFN-alfa is 4 – 6 months. Recently, promising results of targeted therapy for patients with metastatic renal cell cancer have been reported. Both surafenib and sunitimib, oral multitargeted inhibitors of VEGF and PDGF receptors, have demonstrated efficacy in the second-line setting, resulting in FDA approval. Two studies of targeted therapy in the first-line setting for patients with metastatic renal cell cancer were reported at the June 4, 2006 ASCO Plenary session.
read more
|
BJUI Mini Reviews - Anaemia in the Critically Ill Patient: Monitoring of Erythropoietin Therapy
Thursday, 01 June 2006
In this article we discuss some of these key issues from specific studies with the aim of answering the following questions: (i) For which of the critically ill patients is the administration of rHuEPO a therapeutic option? (ii) Which biochemical serum markers and haematological blood cell indices predict an early response to rHuEPO administration, and indicate iron demand in the bone marrow? (iii) Is it possible to use a predictive model which can be used to adequately monitor rHuEPO response and FID?
Login to read more...
|
AUA 2006 - BIOGLUE®: Moving Toward A Surtureless Partial Nephrectomy
Wednesday, 24 May 2006
Berger, AD et al., New York, NY
V1214
read more
|
AUA 2006 - Laparoscopic Partial Nephrectomy For Multiple Renal Tumors
Wednesday, 24 May 2006
Vira, MA et al., Bethesda, MD
V1213
read more
|
AUA 2006 - The Impact Of Lymphadenectomy At The Time Of Nephrectomy For Metastatic RCC
Wednesday, 24 May 2006
Leibovich, BC et al., Rochester, MN
Abstract 1115
read more
|
AUA 2006 - A Comparison Of Nephron-Sparing Techniques: Percutaneous Radiofrequency Ablation (RFA) VS. Open And Laparoscopic Partial Nephrectomy
Wednesday, 24 May 2006
Feldman AS, et al., Boston, MA
Abstract 1114
read more
|
AUA 2006 - Stage Migration In Renal Cell Carcinoma Patients Demonstrated By Analysis Of The National Cancer Database
Wednesday, 24 May 2006
1993-2003. Kane CJ, et al., San Francisco, CA.
Abstract 1105
read more
|
AUA 2006 - Prognostic Factors And Long-Term Outcome Following Resection Of Renal Cell Carcinoma With Right Atrial Extension:Impact On Survival And Benefits Of Immunotherapy
Wednesday, 24 May 2006
Lam, JS et al., Los Angeles, CA
Abstract 1099
read more
|
AUA 2006 - Metachronous Contralateral Renal Cell Carcinoma: Influence Of Race And Tumor Histology
Wednesday, 24 May 2006
Kwon, EO, et al., New York, NY
Abstract 1097
read more
|
AUA 2006 - Association Of Abnormal Preoperative Laboratory Values With Survival Following Radical Nephrectomy For Clinically Confined
Wednesday, 24 May 2006
Magera, JS, Rochester, MN.
Abstract 1095
read more
|
AUA 2006 - Point-Counterpoint Debate On “Should A Small Renal Lesion Be Monitored Or Ablated”
Wednesday, 24 May 2006
Dr. S. Larry Goldenberg, University of British Columbia moderated a debate on "Should a Small Renal Lesion be Monitored or Ablated" at the plenary session of the AUA on Tuesday May 23, 2006.
read more
|
AUA 2006 - Renal Cryoablation: 5 Year Outcomes
Wednesday, 24 May 2006
Hegarty, NJ, et al., Cleveland, OH.
Abstract 1091
read more
|
AUA 2006 - Separation Of Chromphobe Renal Cell Carcinoma From Oncocytoma And Clear Cell Carcinoma: An Otimal Immunohistochemical
Wednesday, 24 May 2006
Liu, L, et al, Glen Allen, VA
Abstract 1088
read more
|
AUA 2006 - Kidney and Ureteral Cancer: Basic Research Discussed Poster Session 6
Tuesday, 23 May 2006
This session represented several abstracts dealing with the molecular pathology of renal cell carcinoma as well as investigations directed towards identifying novel tumor markers of progression and outcome in renal cell carcinoma.
read more
|
AUA 2006 - Immune Mediated Survival Advantage And Primary Tumor Control Of Cryoablation Compared To Nephrectomy In A Murine Model Of Advanced Renal Cancer
Tuesday, 23 May 2006
Hedican, SP, et al., Madison, WI
Abstract 404
An interesting study by Hedican and colleagues suggests that energy ablative therapies such as cryoablation may offer more than just local tumor control, by augmenting host immune function, to improve survival.
read more
|
AUA 2006 - Osteopontin Expressions In Metastatic Renal Cell Carcinoma
Tuesday, 23 May 2006
Carmack AJK, et al., Miami, FL
Abstract 392
The expression of osteopontin, a secreted glycoprotein, was examined in both the primary tumor and metastases from RCC.
read more
|
AUA 2006 - PD-1 Expressionby Tumor Infiltrating Lymphocytes Is Associated With Poor Prognosis In Renal Cell Carcinoma Patients
Tuesday, 23 May 2006
PD-1 Expressionby Tumor Infiltrating Lymphocytes Is Associated With Poor Prognosis In Renal Cell Carcinoma Patients Thompson, RH, et al., Rochester, MN
read more
|
AUA 2006 - Rare Expression Or Mutation Of C-Kit In Grade 4 Renal Cell Carcinoma With Or Without Sarcomatoid Differentiation
Tuesday, 23 May 2006
Sengupta S, et al., Rochester, MN
Abstract 383
Previous studies have suggested that RCC with sarcomatoid differentiation express c-kit, and thus might be responsive to therapy with imatinib (Gleevec™).
read more
|
AUA 2006 - The Cell Of Origin Of Clear Cell Renal Carcinoma - Revisited
Tuesday, 23 May 2006
Tran, MGB et al. United Kingdom
Abstract 368
Tran and colleagues use immunohistochemistry for CD 10, N-cadherin, M2PK, CK 19, E-cadherin, and Tamm-Horsefall protein to gain further insight as to the cell of origin for clear cell renal cell carcinoma (ccRCC), which has been proposed to originate from the proximal tubule cells of the nephron. AUA 2006 - The Cell Of Origin Of Clear Cell Renal Carcinoma - Revisited
read more
|
AUA 2006 - Mononuclear Cell Infiltration In Clear Cell Renal Cell Carcinoma Independently Predicts Patients Survival
Tuesday, 23 May 2006
Webster, WS, et al., Rochester, MN
Abstract 746
In this study of 306 patients, primary tumor specimens were characterized for the presence and extent of lymphocyte infiltration as a function of cancer specific survival (CSS).
read more
|
AUA 2006 - Resection Of Nodal Disease In Patients With Metastatic Conventional Renal Cell Carcinoma Improves Survival
Tuesday, 23 May 2006
Brassel, S, et al., Houston, TX
Abstract 743
Aggressive surgical resection of nodal disease in the setting of cytoreductive surgery for metastatic RCC was evaluated in this study out of M. D. Anderson.
read more
|
AUA 2006 - Microvascular Invasion Is Associated With Aggresive Clinicopatholigcal Features And Is An Independent Predictor Of Survival For Patients With Clear Cell Renal Cell Carcinoma
Tuesday, 23 May 2006
Lam, JS, et al., Los Angeles, CA
Abstract 741
In this study of 973 patients, microvascular invasion (MVI) was identified in 12.4%.
read more
|
AUA 2006 - Cancer-Specific Mortality Is Increased By Erythrocyte Transfusion In Patients Undergoing Surgery For Renal Cell Carcinoma
Tuesday, 23 May 2006
Abstract 733
Routh and colleagues out of Mayo reviewed the records on 2442 renal surgeries for cancer to determine the relationship between perioperative transfusions and cancer specific survival (CSS).
read more
|
AUA 2006 - Renal Cell Carcinoma Sub-Typing By Real-Time PCR On Needle Biopsy.
Tuesday, 23 May 2006
Barocas, DA, et al, New York, NY
Abstract 724
Ex vivo biopsies were performed on 77 renal masses in 72 patients and evaluated for carbonic anhydrase 9 (CA9), chloride channel (CLCNKB), and alpha-methylacyl coenzyme A racemase (AMACR) through real time PCR techniques.
read more
|
AUA 2006 - Are Small Renal Tumors Harmless? Analysis Of Histopathological Features According To Tumor Size In Tumors 4 CM or Less In Diameter
Tuesday, 23 May 2006
Remzi, M., et al, Vienna, Austria
Abstract 711
In this study, the authors examined 287 nephrectomy specimens to correlate tumor size with biological potential.
read more
|
AUA 2006 - High Expression Levels of Survivin Protein Are An Independent Predictor Of Poor Outcome Among Patients Treated Surgically For Clear Cell Renal Cell Carcinoma
Tuesday, 23 May 2006
Parker, AS et al., Rochester, MN.
Abstract 710
Gene array data was utilized to demonstrate that survivin mRNA expression was associated with a worse outcome in conventional RCC.
read more
|
AUA 2006 - Society of Urologic Oncology Meeting: Willet F. Whitmore Jr. Lecture: Kidney Cancer: Past, Present and Future
Monday, 22 May 2006
The annual meeting of the Society of Urologic Oncology took place on Saturday, May 20, 2006 during the annual American Urological Association Meeting in Atlanta, Georgia. Dr. Andrew C. Novick, Cleveland Clinic Foundation gave the Willet F. Whitmore Jr. Lecture: Kidney Cancer: Past, Present and Future.r
read more
|
AUA 2006 - Enucleation of Renal Cell Carcinoma with Laser Ablation of Tumor Base: Cancer Control Comparable to Tradtional Partial Nephrectomy
Sunday, 21 May 2006
Moderate Poster Session Saturday, May 20, 2006 1:00 PM - 3:00 PM.
read more
|
AUA 2006 - Clinical Stage T1A Renal Tumors: Retrospective Study Shows Radiofrequency Ablation Comparable to Partial Nephrectomy
Sunday, 21 May 2006
Moderate Poster Session Saturday, May 20, 2006 1:00 PM - 3:00 PM.
read more
|
AUA 2006 - Targeted Therapy For Renal Cell Carcinoma
Sunday, 21 May 2006
Dr. Robert Uzzo from Fox Chase Cancer Center summarized the available data on new oral and parenteral therapies for renal cancer. Avastin, working via the VEGF pathway, was studied in patients who had failed prior immunotherapy, resulting in a partial response rate of 10%.
read more
|
Renal Cancer 
